CAJ | 학술논문

目的：探讨精囊蛋白SG1在肾透明细胞癌患者癌旁组织和癌组织中的表达差异，结合临床指标，研究其临床意义。方法以qRT-PCR检测24例明确诊断为肾透明细胞癌患者的癌组织和癌旁组织中的SG1表达水平，以免疫组化研究53例肾透明细胞癌标本中的SG1蛋白表达水平，并进一步研究其临床意义。结果 qRT-PCR 显示癌组织中的 SG1水平明显低于癌旁组织的（P＜0.01）。53例癌组织中，抗SG1免疫组化染色30例阳性（57%），明显低于对应癌旁组织的全部阳性（100%）。SG1表达量和肾透明细胞癌临床分期呈负相关（pT1～2 vs. pT3～4，P＜0.0001），且SG1表达阴性的患者复发概率升高（P＜0.01）。结论 SG1在肾透明细胞癌中为低表达，SG1可预测肾透明细胞癌的进展和预后。
목적：탐토정낭단백SG1재신투명세포암환자암방조직화암조직중적표체차이，결합림상지표，연구기림상의의。방법이qRT-PCR검측24례명학진단위신투명세포암환자적암조직화암방조직중적SG1표체수평，이면역조화연구53례신투명세포암표본중적SG1단백표체수평，병진일보연구기림상의의。결과 qRT-PCR 현시암조직중적 SG1수평명현저우암방조직적（P＜0.01）。53례암조직중，항SG1면역조화염색30례양성（57%），명현저우대응암방조직적전부양성（100%）。SG1표체량화신투명세포암림상분기정부상관（pT1～2 vs. pT3～4，P＜0.0001），차SG1표체음성적환자복발개솔승고（P＜0.01）。결론 SG1재신투명세포암중위저표체，SG1가예측신투명세포암적진전화예후。
Objective The incidence of clear cell renal cell carcinoma (ccRCC) has been steadily rising each year. There are currently few recognized biomarkers for the diagnosis and prognosis of ccRCC. We investigated Semenogelin I (SG1) expression and its clinical significance in patients with ccRCC. Methods The expression level of SG1 was measured by qRT-PCR. Immunohistochemistry was used to investigate the protein expression of SG1 in ccRCC and normal renal tissue from 53 patients. The Kaplan-Meier method and log-rank test were used to evaluate the data. Results By qRT-RCR (P<0.01), the level of SG1 expression in benign tissues was higher than that in ccRCC tissues. Expression of SG1 was observed in 30 (57%) ccRCC, which was significantly lower than that observed in benign renal tissues from the same patients [SG1-positive in 53 (100%) cases (P<0.01)] by immunohistochemistry. There was an inverse relation between SG1 expression and clinical stage (pT1-2 vs. pT3-4, P<0.000 1). Patients with SG1-negative tumors had a significantly higher risk of recurrence (Kaplan-Meier and Log-rank tests, P<0.01). Conclusion There is low SG1 expression in ccRCC. SG1 expression has potential value in predicting cancer progression and prognosis. These findings support the use of SG1 as a novel biomarker for ccRCC.